CSPC Pharmaceutical Group stock
1093.HKHKSECSPC Pharmaceutical Group Limited, HealthcareISIN HK1093012172
79Score 79 out of 100, Strong
Price and trend
63 / 100
Price history
+9.7% in one yearThe chart shows daily closes over 20 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Below the 200-day line: the price is 3.5% below it.
Since September 2026 the 50-day line has been above the 200-day line; the trend has turned up.
Normal: the price is neither overheated nor sold off (RSI 51).
The price is 21% below its 52-week high. Largest decline in 20 years: 79% (April 2010 to June 2012).
Chart figures for advanced users
- SMA 50$1.13
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$1.10
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)51
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$0.84
- The lowest closing price of the last twelve months.
- Resistance$1.36
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- CSPC Pharmaceutical Group Limited belongs to the Drug Manufacturers (General) industry (China) and, with a market value of $12.16B, is number 22 of 27 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $3.8B (down 14.2% year on year) and earnings of $567.11M (down 14.2%).
- MEQIRI Score 79 out of 100 (Strong): rank 24 of 702 in Healthcare, median 53.
Show more
- The P/E is 11.1 (Drug Manufacturers (General) median 17.3, own median of recent years 20.6).
- Our model puts fair value at $1.49, with the price 28% below it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- More cash than debtCash $2.77B, financial debt $97.83M.Stability 80
- Earnings turn into cashFree cash flow 167% of earnings over the last 12 months.Fundamentals 100
- High marginNet margin 23.7% over the last 12 months, Healthcare sector median 13.9%.Profitability 92
Weaknesses
- Analysts expect falling earningsDown 12.6% a year through 2028 (estimates from 20 analysts).Growth 63
- Margin fallingOperating margin 15.3%, average of the prior years 21.9% (to 2024).
- Volatile share priceVolatility 47% a year over the last 12 months.
Its standout strengths are fundamentals and profitability.
Daily figure as of 13 Nov 2026
How the score is calculatedScore overview
Fundamentals are strong, with stable profits and strong cash generation.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk not measured
How well MEQIRI warnsFor stocks from Japan, China, Hong Kong, Taiwan, Korea, Canada, India and Brazil we only show crash risk once a separate backtest shows that it warns as well there as in the US and Europe.
Valuation
Valuation signal
Modestly undervaluedIn our model the price counts as cheap below $1.06 and expensive above $2.48 (uncertainty high, based on the price swings of the past year).
The two parts of the fair value come to $1.32 (cash-flow model) and $1.66 (industry comparison), and the gap between them shows how uncertain the estimate is. The price is below both.
Calculated with a cost of equity of 7.3%. At 8.3% the fair value would be $1.38, at 6.3% it would be $1.66.
Valuation metrics
Half from the cash-flow model, half from earnings times the industry P/E (17.3).
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Jun 2026, revenue rose 18.8% on the twelve months before. Revenue has grown solidly since 2006, at about 11% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 66%, operating 15%, net 15%. Last 12 months: net 24%.
Debt & balance sheet
latest quarterThe balance sheet is solid, with low debt and comfortable interest coverage.
Earnings
- Next earnings
- 24 Mar 2027in 131 days
- Last reported
- 20 Aug 2026EPS reported 0.62 (expected 0.16)above expectations
Analyst estimates
Earnings estimates have barely changed since 28 Oct 2026.
- Earnings per share
- 0.77+0.1%
- Revenue
- $5.02B+0.1%
- Earnings per share
- 0.54+0.1%
- Revenue
- $4.69B+0.1%
MEQIRI has stored the estimates since 28 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
What happened at CSPC Pharmaceutical Group
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
702 rated companies in Healthcare
- This company
- 79
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Drug Manufacturers (General)
The next larger and next smaller companies by market value
- BiogenBIIB $37.03B60
- Daiichi Sankyo4568.T $32.6B73
- Astellas Pharma4503.T $30.07B87
- OrionORNBV.HE $15.97B86
- Zhangzhou Pientzehuang Pharmaceutical.600436.SS $11.75B58
- GrifolsGRF.MC $8.79B66
- Ono Pharmaceutical4528.T $7.32B74
- OrganonOGN $3.65B59
ETFs that hold CSPC Pharmaceutical Group
Held by 52 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| iShares Dow Jones China Offshore 50 UCITS ETF (DE)EXXU | 0.57% | 0.62% | €40.6M |
| Franklin EM Multi-Factor Equity UCITS ETFFLXE | 0.57% | 0.30% | €102.64M |
| Deka MSCI China ex A Shares UCITS ETFEL46 | 0.52% | 0.65% | €73.86M |
Show 5 more
| UBS MSCI China Universal UCITS ETF USD disUETC | 0.41% | 0.30% | €132.6M |
| Fidelity Emerging Markets Quality Income UCITS ETF ACC-USDFYEM | 0.38% | 0.50% | €247.81M |
| iShares MSCI EM Consumer Growth UCITS ETFCEMG | 0.37% | 0.60% | €31.52M |
| Xtrackers MSCI China UCITS ETF 1CXCS6 | 0.37% | 0.65% | €1.51B |
| L&G Asia Pacific ex Japan Equity UCITS ETFETLK | 0.35% | 0.10% | €694.16M |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 12 Nov 2026 ($1 = HK$7.8782, $1 = CN¥6.6683)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Strong, published since 7 Nov 2026 (in the score history since 2 Oct 2026)
- Valuation signal Fairly valued since 8 Nov 2026, previously Undervalued
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.